CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $600,709 | -10.0% | 16,231 | +2.0% | 0.00% | -20.0% |
| Q1 2024 | $667,575 | +22.3% | 15,906 | +15.6% | 0.01% | +25.0% |
| Q4 2023 | $545,642 | +73.4% | 13,758 | +20.3% | 0.00% | +33.3% |
| Q3 2023 | $314,719 | -17.7% | 11,436 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $382,425 | -2.6% | 11,271 | +3.2% | 0.00% | -25.0% |
| Q1 2023 | $392,794 | -16.5% | 10,917 | +3.4% | 0.00% | -20.0% |
| Q4 2022 | $470,570 | +64.5% | 10,558 | +3.9% | 0.01% | +66.7% |
| Q3 2022 | $286,000 | +4.8% | 10,164 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $273,000 | -20.6% | 10,117 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $344,000 | -11.1% | 10,091 | +0.8% | 0.00% | 0.0% |
| Q4 2021 | $387,000 | -32.1% | 10,008 | -5.1% | 0.00% | -40.0% |
| Q3 2021 | $570,000 | +58.3% | 10,550 | -1.9% | 0.01% | +66.7% |
| Q2 2021 | $360,000 | +51.9% | 10,755 | -6.6% | 0.00% | +50.0% |
| Q1 2021 | $237,000 | +19.1% | 11,518 | +1.5% | 0.00% | 0.0% |
| Q4 2020 | $199,000 | – | 11,347 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |